The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2022 | Looking beyond BCL-2 inhibition in AML: the potential role of MCL-1 inhibitors and BCLxL inhibitors
Marina Konopleva, MD, PhD, Albert Einstein College of Medicine, New York, NY, discusses approaches to treating acute myeloid leukemia (AML) beyond BCL-2 inhibition, drawing focus on MCL-1 and BCLxL inhibition. Prof. Konopleva first explains the importance of investigating other inhibitors outside of venetoclax, especially for patients who develop resistance to this agent. Following this, Prof. Konopleva highlights some agents being investigated and their potential role in the future treatment of AML. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
